Faramand, R. G., Locke, F. L. (2025). Intermediate-affinity CD19-directed CAR T cell product obecabtagene autoleucel demonstrates favourable safety and efficacy in R/R B-ALL. Nature Reviews Clinical Oncology. https://doi.org/10.1038/s41571-025-00993-4